GO
Loading...

Amylin CEO on Exenatide

Tuesday, 8 Nov 2011 | 5:53 PM ET

Dan Bradbury, Amylin CEO, discusses paying Lilly $250M upfront and $1.2B of future sales for the rights to Exenatide, the once weekly version of diabetes drug, Byetta, that's pending FDA approval.